Thursday 16 October, 2025
Objectives: To evaluate the predictive performance and adequacy of five population pharmacokinetic (popPK) models of meropenem in critically ill adult…
Read morePoster: Clinical Applications
Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections
Thursday 16 October, 2025
Introduction: Tigecycline is considered an appropriate agent for the treatment of complicated infections.[1] Its efficacy has been related to the…
Read moreAssessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients
Thursday 16 October, 2025
Introduction: Tocilizumab is a humanized monoclonal antibody approved for the treatment of rheumatoid arthritis (RA) that competitively inhibits interleukin 6…
Read morePopulation pharmacokinetics suggests that an intraperitoneal daily dose of 750 mg meropenem is sufficient to treat peritonitis in patients undergoing automated peritoneal dialysis
Thursday 16 October, 2025
Objectives: Peritonitis is a serious complication of peritoneal dialysis (PD). In general, intraperitoneal (i.p.) application of antimicrobial agents is known to…
Read moreQuantitative Systems Pharmacology Model of Type 1 IFN-mediated Inflammation in Systemic Lupus Erythematosus
Thursday 16 October, 2025
Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease with complex heterogeneous etiology and pathophysiology, effectively treated with compounds targeting…
Read morePopulation pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 ICU patients
Thursday 16 October, 2025
Introduction: COVID-19 ICU patients receive thromboprophylaxis with low molecular weight heparin (LMWH).[1] However, optimal dose regimens achieving target anti-Xa levels…
Read moreNovel user-friendly applications for dose individualization of sunitinib and imatinib
Thursday 16 October, 2025
Objectives: Therapeutic drug monitoring (TMD) and dose individualization can contribute to increased benefits for patients by augmenting the efficacy and/or…
Read morePopulation pharmacokinetics of vancomycin in Pakistani patients: Dosing simulations based on renal status
Thursday 16 October, 2025
Background: Vancomycin is a narrow therapeutic agent and there is a need to optimize the dose of vancomycin for achieving…
Read morePharmacokinetics of inhaled AZD4604 supports lack of JAK1 systemic activity at therapeutic dose
Thursday 16 October, 2025
Background: AZD4604 is a small molecule selective JAK1 inhibitor, in development for the treatment of asthma [1,2]. Janus kinase inhibitors (JAKis)…
Read moreModel predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation.
Thursday 16 October, 2025
Objectives: Model qualification (transfer between populations), treatment of interoccasion variability (IOV) and downweighing of observations are relevant issues in TDM…
Read more